Cravath, Davis Polk Steer J&J’s $14.6 Billion Intra-Cellular Buy

Cravath, Swaine & Moore guided Johnson & Johnson in its $14.6 billion plan to purchase Intra-Cellular Therapies Inc., a company focused on treatments for central nervous systems. Davis Polk & Wardwell steered Intra-Cellular.

The transaction is the largest in biotech in more than a year, following a broader slump in healthcare M&A in 2024.

Cravath’s team is led by partners Robert I. Townsend III, Ting S. Chen and Jin-Kyu Baek on M&A matters; partners J. Leonard Teti II and Andrew T. Davis on tax matters; partner Matthew J. Bobby on executive compensation and benefits matters; partner Sasha Rosenthal-Larrea on intellectual ...